Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez-Skinner A, Roy U, Mosley RL, Kanmogne G, Liu X, Kabanov AV, Bronich T, McMillan J, Gendelman HE.

Int J Nanomedicine. 2011;6:3393-404. doi: 10.2147/IJN.S27830. Epub 2011 Dec 20.

2.

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, Ma Z, Graham S, Chaubal M, Werling J, Rabinow B, Dou H, Gendelman HE.

Nanomedicine (Lond). 2009 Dec;4(8):903-17. doi: 10.2217/nnm.09.71.

3.

Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.

Nowacek AS, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, Mosley RL, Kanmogne G, Kabanov AV, Bronich T, Gendelman HE.

J Control Release. 2011 Mar 10;150(2):204-11. doi: 10.1016/j.jconrel.2010.11.019. Epub 2010 Nov 23.

4.

Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.

Puligujja P, McMillan J, Kendrick L, Li T, Balkundi S, Smith N, Veerubhotla RS, Edagwa BJ, Kabanov AV, Bronich T, Gendelman HE, Liu XM.

Nanomedicine. 2013 Nov;9(8):1263-73. doi: 10.1016/j.nano.2013.05.003. Epub 2013 May 13.

5.

Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE.

J Neuroimmune Pharmacol. 2010 Dec;5(4):592-601. doi: 10.1007/s11481-010-9198-7. Epub 2010 Mar 17.

6.

Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.

Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, Gorantla S, Balkundi S, Smith N, Alnouti Y, Gautam N, Zhou Y, Poluektova L, Kabanov A, Bronich T, Gendelman HE.

Int J Nanomedicine. 2012;7:2373-88. doi: 10.2147/IJN.S29454. Epub 2012 May 8.

7.

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.

Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, Velinova-Donga M, Kandoussi H, Sevinsky H, Bertz R.

Antivir Ther. 2013;18(7):931-40. doi: 10.3851/IMP2674. Epub 2013 Aug 20.

PMID:
23963204
8.

Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.

Martinez-Skinner AL, Veerubhotla RS, Liu H, Xiong H, Yu F, McMillan JM, Gendelman HE.

J Proteome Res. 2013 May 3;12(5):2282-94. doi: 10.1021/pr400185w. Epub 2013 Apr 17.

9.

Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

Mehling M, Drechsler H, Kuhle J, Hardmeier M, Doerries R, Ruegg S, Gass A.

J Neurovirol. 2008 Jan;14(1):78-84. doi: 10.1080/13550280701793940.

PMID:
18300078
10.

Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.

Puligujja P, Balkundi SS, Kendrick LM, Baldridge HM, Hilaire JR, Bade AN, Dash PK, Zhang G, Poluektova LY, Gorantla S, Liu XM, Ying T, Feng Y, Wang Y, Dimitrov DS, McMillan JM, Gendelman HE.

Biomaterials. 2015 Feb;41:141-50. doi: 10.1016/j.biomaterials.2014.11.012. Epub 2014 Dec 9.

11.

Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Gautam N, Roy U, Balkundi S, Puligujja P, Guo D, Smith N, Liu XM, Lamberty B, Morsey B, Fox HS, McMillan J, Gendelman HE, Alnouti Y.

Antimicrob Agents Chemother. 2013 Jul;57(7):3110-20. doi: 10.1128/AAC.00267-13. Epub 2013 Apr 22.

12.

A maintenance dose of atazanavir/ritonavir 200/100 mg once daily is effective in virologically suppressed HIV-1-infected patients.

Lanzafame M, Lattuada E, Rigo F, Vento S.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e81-2. doi: 10.1097/QAI.0b013e3182928f10. No abstract available.

PMID:
23666142
13.

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

Dumond JB, Adams JL, Prince HM, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD.

HIV Med. 2013 Aug;14(7):401-9. doi: 10.1111/hiv.12017. Epub 2013 Feb 24.

14.

Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage.

Bressani RF, Nowacek AS, Singh S, Balkundi S, Rabinow B, McMillan J, Gendelman HE, Kanmogne GD.

Nanotoxicology. 2011 Dec;5(4):592-605. doi: 10.3109/17435390.2010.541292. Epub 2010 Dec 22.

15.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team.

JAMA. 2006 Aug 16;296(7):806-14.

PMID:
16905786
16.

Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

Dash PK, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RL, Gelbard HA, McMillan J, Gorantla S, Poluektova LY.

AIDS. 2012 Nov 13;26(17):2135-44. doi: 10.1097/QAD.0b013e328357f5ad.

17.

Macrophage endocytic trafficking of antiretroviral nanoparticles.

Kadiu I, Nowacek A, McMillan J, Gendelman HE.

Nanomedicine (Lond). 2011 Aug;6(6):975-94. doi: 10.2217/nnm.11.27. Epub 2011 Mar 21.

18.

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.

Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group.

J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21.

19.

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.

Antivir Ther. 2006;11(4):421-9.

PMID:
16856615
20.

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, Gelinck L, Kroon F, Wit FW, Van Schaik RH, Kuks PF, Burger DM.

AIDS. 2010 May 15;24(8):1223-6. doi: 10.1097/QAD.0b013e3283389129.

PMID:
20299957
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk